Research programme: anti-RANKL therapeutics - Pharmexa

Drug Profile

Research programme: anti-RANKL therapeutics - Pharmexa

Alternative Names: AutoVac RANKL vaccine - Pharmexa; ME 107; Osteoporosis vaccine - Pharmexa; PX 107; PX 107 RANKL AutoVac; RANKL AutoVac; RANKL vaccine - Pharmexa

Latest Information Update: 25 Jun 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmexa
  • Class Vaccines
  • Mechanism of Action Bone resorption factor inhibitors; Immunostimulants; Osteoclast inhibitors; RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone disorders; Osteoporosis

Most Recent Events

  • 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
  • 27 Feb 2008 Suspended - Preclinical for Bone disorders in Denmark (Parenteral)
  • 27 Feb 2008 Suspended - Preclinical for Osteoporosis in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top